Infant Bacterial Therapeutics AB (publ) announced earnings results for the second quarter and six months ended September 30, 2018. For the quarter, the company reported operating loss of SEK 7,683,000 compared to SEK 4,571,000 a year ago. Loss after financial items are SEK 7,985,000 compared to SEK 4,586,000 a year ago. Loss for the period was SEK 7,985,000 compared to SEK 4,586,000 a year ago. Loss per share before and after diluted was SEK 0.71 compared to SEK 0.78 a year ago. Cash used in operating activities was SEK 9,042,000 compared to SEK 9,147,000 a year ago. For the six months, the company reported operating loss of SEK 15,541,000 compared to SEK 27,082,000 a year ago. Loss after financial items are SEK 16,464,000 compared to SEK 27,097,000 a year ago. Loss for the period was SEK 16,464,000 compared to SEK 27,097,000 a year ago. Loss per share before and after diluted was SEK 1.55 compared to SEK 4.61 a year ago. Cash used in operating activities was SEK 20,823,000 compared to SEK 27,444,000 a year ago.